BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) have been given an average rating of “Moderate Buy” by the five brokerages that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $25.00.

A number of analysts recently commented on BBOT shares. Stifel Nicolaus started coverage on BridgeBio Oncology Therapeutics in a research note on Tuesday, February 10th. They set a “buy” rating and a $23.00 price objective on the stock. HC Wainwright increased their price objective on BridgeBio Oncology Therapeutics from $27.00 to $29.00 and gave the company a “buy” rating in a research note on Friday, March 6th. Wall Street Zen lowered BridgeBio Oncology Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday. Finally, Canaccord Genuity Group started coverage on BridgeBio Oncology Therapeutics in a research note on Monday, May 11th. They set a “buy” rating and a $23.00 price objective on the stock.

BridgeBio Oncology Therapeutics Stock Performance

Shares of BBOT stock opened at $8.51 on Monday. BridgeBio Oncology Therapeutics has a fifty-two week low of $7.60 and a fifty-two week high of $14.87. The stock has a market capitalization of $681.71 million, a PE ratio of -5.60 and a beta of 0.22. The firm has a fifty day moving average price of $8.91.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($526.11) earnings per share for the quarter. Analysts forecast that BridgeBio Oncology Therapeutics will post -2.18 EPS for the current year.

Institutional Trading of BridgeBio Oncology Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. CIBC Private Wealth Group LLC acquired a new position in shares of BridgeBio Oncology Therapeutics in the 4th quarter valued at about $63,000. Persistent Asset Partners Ltd acquired a new position in shares of BridgeBio Oncology Therapeutics in the 4th quarter valued at about $107,000. Squarepoint Ops LLC acquired a new position in shares of BridgeBio Oncology Therapeutics in the 4th quarter valued at about $144,000. Quadrature Capital Ltd acquired a new position in shares of BridgeBio Oncology Therapeutics in the 4th quarter valued at about $162,000. Finally, BIT Capital GmbH acquired a new position in shares of BridgeBio Oncology Therapeutics in the 4th quarter valued at about $313,000. 54.89% of the stock is owned by institutional investors and hedge funds.

BridgeBio Oncology Therapeutics Company Profile

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.